Top movers in Tuesday's after hours session
By Mill Chart
Last update: Apr 9, 2024
Get insights into the top gainers and losers of Tuesday's after-hours session.
Today's after hours gainers
| Ticker | Change | Comment |
|---|---|---|
| MRIN | 68.97% | Impressive after-hours gains for MARIN SOFTWARE INC (NASDAQ:MRIN) as its stock price advanced 68.97% to $0.49 during Tuesday's after-hours session. Earlier today the company had a press release: Marin Software Enhances Its Microsoft Advertising Integration. |
| INAB | 31.19% | Positive after-hours movement for IN8BIO INC (NASDAQ:INAB) as its shares recorded a 31.19% increase, reaching $1.43 during Tuesday's after-hours session. Earlier today the company had a press release: IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024. |
| LIFE | 9.83% | After the regular session, ATYR PHARMA INC (NASDAQ:LIFE) continues to impress in the after-hours session, with a 9.83% increase to $1.89. In the last 6 months the stock gained 23.74%. |
| PFMT | 8.96% | PERFORMANT FINANCIAL CORP (NASDAQ:PFMT) rose 8.96% to $2.92 during Tuesday's after hours session. Earlier today the company had a press release: Performant Financial Corporation Acquires Artificial Intelligence Technology in Support of Its Scale Initatives. |
| RVMD | 8.46% | REVOLUTION MEDICINES INC's (NASDAQ:RVMD) shares rose 8.46% to $35.78. In the last year the stock gained 49.01%. |
| FTEL | 8.26% | Positive market activity for FITELL CORP (NASDAQ:FTEL) after regular trading hours, with a 8.26% increase to $7.6 in the after-hours session on Tuesday. After today's -10.46% drop, there is a noticeable rebound in NASDAQ:FTEL during today's after-hours session. |
| UCAR | 7.78% | Promising after-hours performance observed for U POWER LTD (NASDAQ:UCAR) as its shares surged 7.78% to $5.68 during Tuesday's after-hours trading. The stock is trading 59.21% lower than 3 months ago. |
| BCLI | 7.3% | BRAINSTORM CELL THERAPEUTICS (NASDAQ:BCLI) showcases remarkable after-hours performance, with a 7.3% rise to $0.63 during Tuesday's after-hours trading. After experiencing a -20.21% decline earlier today, NASDAQ:BCLI shows signs of a rebound in today's after-hours session. |
| JAGX | 6.67% | Positive market activity for JAGUAR HEALTH INC (NASDAQ:JAGX) after regular trading hours, with a 6.67% increase to $0.1 in the after-hours session on Tuesday. Shareholders saw the stock price going 26.05% higher in the past month. |
| ATXI | 6.47% | AVENUE THERAPEUTICS INC's (NASDAQ:ATXI) shares rose 6.47% to $0.16. Shareholders saw the stock price going 75.51% lower is the past 6 months. |
For the full after hours gainers list go to our after hours gainers page.
Today's after hours losers
| Ticker | Change | Comment |
|---|---|---|
| PRFX | -17.22% | Following a -13.21% loss in the regular session, NASDAQ:PRFX exhibits further decline during today's after-hours session. The regular session ended on a negative note with NASDAQ:PRFX closing -13.21% lower, and the after-hours session reflects a continuation of the bearish sentiment. |
| SGH | -11.5% | SMART GLOBAL HOLDINGS INC's (NASDAQ:SGH) stock price decreased by 11.5% to $22.94. The company's earnings where released Yesterday. A press release (SGH Reports Second Quarter Fiscal 2024 Financial Results) was released earlier today. |
| CLDI | -11.29% | After today's 63.16% drop, NYSEARCA:CLDI shows further decline during today's after-hours session with a 11.29% decrease. Despite a strong 63.16% gain earlier today, NYSEARCA:CLDI is experiencing a reversal in after-hours trading, with prices declining by 11.29%. A press release (Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024) was released yesterday. |
| SLNA | -11.08% | Price volatility persists as NASDAQ:SLNA closed the regular session with a 96.25% loss, and the downward trend continues in the after-hours session. Price movements remain volatile as NASDAQ:SLNA gives back 96.25% of its earlier gains in the after-hours session. |
| SMFL | -8.96% | SMART FOR LIFE INC's (NASDAQ:SMFL) stock price is declining with 8.96% to a price of $0.61. The stock is trading 20.11% lower than a month ago. |
| WTO | -8.37% | UTIME LTD's (NASDAQ:WTO) shares fell 8.37% to $0.27. The stock is trading 22.79% higher than a month ago. |
| ALBT | -8.11% | AVALON GLOBOCARE CORP's (NASDAQ:ALBT) stock price decreased by 8.11% to $0.34. The positive momentum earlier in the day is waning as NASDAQ:ALBT retraces 14.2% during the after-hours session. |
| BENF | -7.5% | Following a %ABSPERF% loss in the regular session, NASDAQ:BENF exhibits further decline during today's after-hours session. In the last 3 months the share price dropped with 78.54%. |
| HEAR | -7.07% | TURTLE BEACH CORP's (NASDAQ:HEAR) stock price saw a decrease of 7.07% to $15.5 during Tuesday's after-hours session. Earlier today the company had a press release: Turtle Beach Announces Update on Its Return of Capital Strategy to Shareholders. |
| AUUD | -6.76% | AUDDIA INC's (NASDAQ:AUUD) shares fell 6.76% to $2.62. NASDAQ:AUUD already had a hard day: closing -20.62% lower during the regular session. A press release (Auddia Announces Issuance of Core AI Patent) was released two days ago. |
For the full after hours loser list go to our after hours losers page.
BRAINSTORM CELL THERAPEUTICS
NASDAQ:BCLI (4/29/2024, 1:14:57 PM)
0.5479
+0.01 (+2.51%)
BCLI News
13 days ago - BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
18 days ago - BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases,...
19 days ago - BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
20 days ago - ChartmillTop movers in Tuesday's after hours sessionGet insights into the top gainers and losers of Tuesday's after-hours session.
20 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayPre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!
20 days ago - BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
21 days ago - BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics to Provide Update on NurOwn Program/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...
a month ago - InvestorPlaceBCLI Stock Earnings: Brainstorm Cell Beats EPS for Q4 2023BCLI stock results show that Brainstorm Cell beat analyst estimates for earnings per share the fourth quarter of 2023.
a month ago - BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
2 months ago - BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
2 months ago - Seeking AlphaBrainStorm submits SPA request to FDA for Phase 3 study design (NASDAQ:BCLI)BrainStorm Cell Therapeutics (BCLI) said it has submitted a Special Protocol Assessment request to the FDA for a Phase 3b study of its cell therapy NurOwn in the treatment of ALS.
2 months ago - BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
